Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 38

1.

Phase I trial of anti-CS1 monoclonal antibody elotuzumab in combination with bortezomib in the treatment of relapsed/refractory multiple myeloma.

Jakubowiak AJ, Benson DM, Bensinger W, Siegel DS, Zimmerman TM, Mohrbacher A, Richardson PG, Afar DE, Singhal AK, Anderson KC.

J Clin Oncol. 2012 Jun 1;30(16):1960-5. doi: 10.1200/JCO.2011.37.7069. Epub 2012 Jan 30.

2.

A phase 1, multicenter, open-label, dose escalation study of elotuzumab in patients with advanced multiple myeloma.

Zonder JA, Mohrbacher AF, Singhal S, van Rhee F, Bensinger WI, Ding H, Fry J, Afar DE, Singhal AK.

Blood. 2012 Jul 19;120(3):552-9. doi: 10.1182/blood-2011-06-360552. Epub 2011 Dec 19.

3.

Combinatorial efficacy of anti-CS1 monoclonal antibody elotuzumab (HuLuc63) and bortezomib against multiple myeloma.

van Rhee F, Szmania SM, Dillon M, van Abbema AM, Li X, Stone MK, Garg TK, Shi J, Moreno-Bost AM, Yun R, Balasa B, Ganguly B, Chao D, Rice AG, Zhan F, Shaughnessy JD Jr, Barlogie B, Yaccoby S, Afar DE.

Mol Cancer Ther. 2009 Sep;8(9):2616-24. doi: 10.1158/1535-7163.MCT-09-0483. Epub 2009 Sep 1.

4.

CS1 promotes multiple myeloma cell adhesion, clonogenic growth, and tumorigenicity via c-maf-mediated interactions with bone marrow stromal cells.

Tai YT, Soydan E, Song W, Fulciniti M, Kim K, Hong F, Li XF, Burger P, Rumizen MJ, Nahar S, Podar K, Hideshima T, Munshi NC, Tonon G, Carrasco RD, Afar DE, Anderson KC.

Blood. 2009 Apr 30;113(18):4309-18. doi: 10.1182/blood-2008-10-183772. Epub 2009 Feb 4. Erratum in: Blood. 2009 Sep 24;114(13):2852. Retraction in: Blood. 2010 Apr 8;115(14):2983.

5.

CS1, a potential new therapeutic antibody target for the treatment of multiple myeloma.

Hsi ED, Steinle R, Balasa B, Szmania S, Draksharapu A, Shum BP, Huseni M, Powers D, Nanisetti A, Zhang Y, Rice AG, van Abbema A, Wong M, Liu G, Zhan F, Dillon M, Chen S, Rhodes S, Fuh F, Tsurushita N, Kumar S, Vexler V, Shaughnessy JD Jr, Barlogie B, van Rhee F, Hussein M, Afar DE, Williams MB.

Clin Cancer Res. 2008 May 1;14(9):2775-84. doi: 10.1158/1078-0432.CCR-07-4246.

6.

Anti-CS1 humanized monoclonal antibody HuLuc63 inhibits myeloma cell adhesion and induces antibody-dependent cellular cytotoxicity in the bone marrow milieu.

Tai YT, Dillon M, Song W, Leiba M, Li XF, Burger P, Lee AI, Podar K, Hideshima T, Rice AG, van Abbema A, Jesaitis L, Caras I, Law D, Weller E, Xie W, Richardson P, Munshi NC, Mathiot C, Avet-Loiseau H, Afar DE, Anderson KC.

Blood. 2008 Aug 15;112(4):1329-37. Epub 2007 Sep 28.

7.

Epithelial membrane protein-1 is a biomarker of gefitinib resistance.

Jain A, Tindell CA, Laux I, Hunter JB, Curran J, Galkin A, Afar DE, Aronson N, Shak S, Natale RB, Agus DB.

Proc Natl Acad Sci U S A. 2005 Aug 16;102(33):11858-63. Epub 2005 Aug 8.

8.

Preclinical validation of anti-TMEFF2-auristatin E-conjugated antibodies in the treatment of prostate cancer.

Afar DE, Bhaskar V, Ibsen E, Breinberg D, Henshall SM, Kench JG, Drobnjak M, Powers R, Wong M, Evangelista F, O'Hara C, Powers D, DuBridge RB, Caras I, Winter R, Anderson T, Solvason N, Stricker PD, Cordon-Cardo C, Scher HI, Grygiel JJ, Sutherland RL, Murray R, Ramakrishnan V, Law DA.

Mol Cancer Ther. 2004 Aug;3(8):921-32.

9.

E-selectin up-regulation allows for targeted drug delivery in prostate cancer.

Bhaskar V, Law DA, Ibsen E, Breinberg D, Cass KM, DuBridge RB, Evangelista F, Henshall SM, Hevezi P, Miller JC, Pong M, Powers R, Senter P, Stockett D, Sutherland RL, von Freeden-Jeffry U, Willhite D, Murray R, Afar DE, Ramakrishnan V.

Cancer Res. 2003 Oct 1;63(19):6387-94.

10.

Expression of the zinc transporter ZnT4 is decreased in the progression from early prostate disease to invasive prostate cancer.

Henshall SM, Afar DE, Rasiah KK, Horvath LG, Gish K, Caras I, Ramakrishnan V, Wong M, Jeffry U, Kench JG, Quinn DI, Turner JJ, Delprado W, Lee CS, Golovsky D, Brenner PC, O'Neill GF, Kooner R, Stricker PD, Grygiel JJ, Mack DH, Sutherland RL.

Oncogene. 2003 Sep 4;22(38):6005-12.

PMID:
12955079
11.

Use of a SCID mouse model to select for a more aggressive strain of prostate cancer.

Davies MR, Lee YP, Lee C, Zhang X, Afar DE, Lieberman JR.

Anticancer Res. 2003 May-Jun;23(3B):2245-52.

PMID:
12894499
12.

Survival analysis of genome-wide gene expression profiles of prostate cancers identifies new prognostic targets of disease relapse.

Henshall SM, Afar DE, Hiller J, Horvath LG, Quinn DI, Rasiah KK, Gish K, Willhite D, Kench JG, Gardiner-Garden M, Stricker PD, Scher HI, Grygiel JJ, Agus DB, Mack DH, Sutherland RL.

Cancer Res. 2003 Jul 15;63(14):4196-203.

13.

Recognition of multiple substrate motifs by the c-ABL protein tyrosine kinase.

Wu JJ, Afar DE, Phan H, Witte ON, Lam KS.

Comb Chem High Throughput Screen. 2002 Feb;5(1):83-91.

PMID:
11860343
14.

Catalytic cleavage of the androgen-regulated TMPRSS2 protease results in its secretion by prostate and prostate cancer epithelia.

Afar DE, Vivanco I, Hubert RS, Kuo J, Chen E, Saffran DC, Raitano AB, Jakobovits A.

Cancer Res. 2001 Feb 15;61(4):1686-92.

15.

STEAP: a prostate-specific cell-surface antigen highly expressed in human prostate tumors.

Hubert RS, Vivanco I, Chen E, Rastegar S, Leong K, Mitchell SC, Madraswala R, Zhou Y, Kuo J, Raitano AB, Jakobovits A, Saffran DC, Afar DE.

Proc Natl Acad Sci U S A. 1999 Dec 7;96(25):14523-8.

16.

Dissection of signaling pathways and cloning of new signal transducers in tyrosine kinase-induced pathways by genetic selection.

Mahlmann S, McLaughlin J, Afar DE, Mohr R, Kay RJ, Witte ON.

Leukemia. 1998 Dec;12(12):1858-65. Review.

17.

Bcl-2-independent Bcr-Abl-mediated resistance to apoptosis: protection is correlated with up regulation of Bcl-xL.

Amarante-Mendes GP, McGahon AJ, Nishioka WK, Afar DE, Witte ON, Green DR.

Oncogene. 1998 Mar;16(11):1383-90.

18.

Regulation of the oncogenic activity of BCR-ABL by a tightly bound substrate protein RIN1.

Afar DE, Han L, McLaughlin J, Wong S, Dhaka A, Parmar K, Rosenberg N, Witte ON, Colicelli J.

Immunity. 1997 Jun;6(6):773-82.

19.

Oligomerization of the ABL tyrosine kinase by the Ets protein TEL in human leukemia.

Golub TR, Goga A, Barker GF, Afar DE, McLaughlin J, Bohlander SK, Rowley JD, Witte ON, Gilliland DG.

Mol Cell Biol. 1996 Aug;16(8):4107-16.

20.

Regulation of Btk by Src family tyrosine kinases.

Afar DE, Park H, Howell BW, Rawlings DJ, Cooper J, Witte ON.

Mol Cell Biol. 1996 Jul;16(7):3465-71.

21.
22.

Regulation of Btk function by a major autophosphorylation site within the SH3 domain.

Park H, Wahl MI, Afar DE, Turck CW, Rawlings DJ, Tam C, Scharenberg AM, Kinet JP, Witte ON.

Immunity. 1996 May;4(5):515-25.

23.

Signaling by ABL oncogenes through cyclin D1.

Afar DE, McLaughlin J, Sherr CJ, Witte ON, Roussel MF.

Proc Natl Acad Sci U S A. 1995 Oct 10;92(21):9540-4.

24.

Alternative signals to RAS for hematopoietic transformation by the BCR-ABL oncogene.

Goga A, McLaughlin J, Afar DE, Saffran DC, Witte ON.

Cell. 1995 Sep 22;82(6):981-8.

25.

Tyrosine phosphorylation of BCR by FPS/FES protein-tyrosine kinases induces association of BCR with GRB-2/SOS.

Maru Y, Peters KL, Afar DE, Shibuya M, Witte ON, Smithgall TE.

Mol Cell Biol. 1995 Feb;15(2):835-42.

26.

Characterization of breakpoint cluster region kinase and SH2-binding activities.

Afar DE, Witte ON.

Methods Enzymol. 1995;256:125-9.

PMID:
7476425
28.

Brief report: a point mutation in the SH2 domain of Bruton's tyrosine kinase in atypical X-linked agammaglobulinemia.

Saffran DC, Parolini O, Fitch-Hilgenberg ME, Rawlings DJ, Afar DE, Witte ON, Conley ME.

N Engl J Med. 1994 May 26;330(21):1488-91. No abstract available.

29.

Differential complementation of Bcr-Abl point mutants with c-Myc.

Afar DE, Goga A, McLaughlin J, Witte ON, Sawyers CL.

Science. 1994 Apr 15;264(5157):424-6.

PMID:
8153630
30.

Genetic approaches to defining signaling by the CML-associated tyrosine kinase BCR-ABL.

Afar DE, Goga A, Cohen L, Sawyers CL, McLaughlin J, Mohr RN, Witte ON.

Cold Spring Harb Symp Quant Biol. 1994;59:589-94. Review. No abstract available.

PMID:
7587117
31.
32.
33.

Multiple cDNAs encoding the esk kinase predict transmembrane and intracellular enzyme isoforms.

Douville EM, Afar DE, Howell BW, Letwin K, Tannock L, Ben-David Y, Pawson T, Bell JC.

Mol Cell Biol. 1992 Jun;12(6):2681-9.

34.

Tyrosine phosphorylation of biliary glycoprotein, a cell adhesion molecule related to carcinoembryonic antigen.

Afar DE, Stanners CP, Bell JC.

Biochim Biophys Acta. 1992 Feb 19;1134(1):46-52.

PMID:
1371937
35.

TIK, a novel serine/threonine kinase, is recognized by antibodies directed against phosphotyrosine.

Icely PL, Gros P, Bergeron JJ, Devault A, Afar DE, Bell JC.

J Biol Chem. 1991 Aug 25;266(24):16073-7.

36.

Cell adhesion properties of myelin-associated glycoprotein in L cell fibroblasts.

Afar DE, Marius RM, Salzer JL, Stanners CP, Braun PE, Bell JC.

J Neurosci Res. 1991 Aug;29(4):429-36.

PMID:
1724267
37.

STY, a tyrosine-phosphorylating enzyme with sequence homology to serine/threonine kinases.

Howell BW, Afar DE, Lew J, Douville EM, Icely PL, Gray DA, Bell JC.

Mol Cell Biol. 1991 Jan;11(1):568-72.

38.

Differential phosphorylation of myelin-associated glycoprotein isoforms in cell culture.

Afar DE, Salzer JL, Roder J, Braun PE, Bell JC.

J Neurochem. 1990 Oct;55(4):1418-26.

PMID:
1697896

Supplemental Content

Support Center